Sequencio Therapeutics Names Emily Tan as COO

Sequencio Therapeutics, the cancer vaccine subsidiary of Hong Kong-listed CK Life Sciences (Stock Code: 0775), has appointed industry veteran Emily Tan as Chief Operating Officer. Announced on 18 May 2026, the move signals that Sequencio is building out the operational architecture needed to advance its therapeutic cancer vaccine pipeline through the next stage of development. Tan brings 30 years of experience across global pharma, contract research and innovative biotech.

Sequencio is developing next-generation therapeutic cancer vaccines designed to harness a patient’s own immune system to achieve durable, long-term remission with a favourable safety profile, targeting the limitations of current standard-of-care therapies. The company’s stated long-term vision is to shift oncology treatment from transient tumour reduction toward sustained, immune-controlled remission. Tan will oversee global operations and execution across that pipeline.

Tan joins from IQVIA, where she was Senior Vice President, Business Development, leading commercial activities across Asia Pacific and supporting clients on global integrated go-to-market strategy. She previously held C-suite roles at China-based biotechs Unixell Biotechnology, Bennu Biotherapeutics and Oricell Therapeutics, scaling operations and leading global Investigational New Drug submissions and China Investigator-Initiated Trial filings. Earlier leadership roles span PAREXEL, Syneos and Pfizer. Dr Melvin Toh, Vice President and Chief Scientific Officer at CK Life Sciences, described the appointment as strengthening the leadership bench as Sequencio advances its pipeline and builds the operational foundation to support its next stage of growth.

The commercial signal here is execution intent. Sequencio’s pipeline depends on coordinated global IND submissions, clinical operations and regulatory navigation across multiple jurisdictions, all areas where Tan’s CRO and China-startup background applies directly. Expect closer attention from the oncology and immuno-therapy investor community as Sequencio moves to convert scientific positioning in therapeutic cancer vaccines into clinical and regulatory progress.